# Analysis of Poisonous Glycols from Blood and Aqueous Samples

# **Table of Contents**

| 1 | Intro        | DUCTION  | 3  |
|---|--------------|--|----|
| 2 | Scope        |  | 3  |
| 3 | Princ        | IPLE   | 3  |
| 4 | SPECIF       | леn Criteria   | 3  |
| 5 | EQUIP        | MENT   | 3  |
|   |              | Equipment  |    |
|   | 5.2          | Consumables  | 4  |
|   | 5.3          | Instruments  | 4  |
|   | 5.4          | Software   | 4  |
|   | 5.5          | Chemicals/Reagents   | 4  |
|   | 5.5.1        | Purchased  | 4  |
|   | 5.5.2        | Prepared   | 5  |
|   | 5.6          | Standards/Controls   | 5  |
|   | 5.6.1        | Purchased/Stocks   | 5  |
|   | 5.6.2        | Prepared   | 5  |
| 6 | Proce        | DURE   | 7  |
|   |              | Screening for EG in Aqueous Matrices                                 |    |
|   | 6.2          | Screening or Confirmation of EG in Blood Specimens (HFBA Derivative) | 7  |
|   | 6.3          | Confirmation: EG, DEG, TEG, PG in Blood; EG in Aqueous Samples       | 8  |
| 7 | Analy        | TICAL PARAMETERS   | 9  |
|   | 7.1          | DART-TOF MS Analysis   | 9  |
|   | 7.1.1        |  |    |
|   | 7.1.2        | TOF-MS Parameters:   | 9  |
|   | 7.2          | GC/MS Parameters for HFBA Derivative                                 | 9  |
|   | 7.2.1        | GC Parameters  | 9  |
|   | 7.2.2        | Mass Spectrometer Parameters   | 9  |
|   | 7.3          | GC/MS Parameters for BSTFA Derivatives                               | 10 |
|   | 7.3.1        | GC Parameters  | 10 |
|   | 7.3.2        | Mass Spectrometer Parameters (El Analysis)                           | 10 |
|   | 7.3.3        | Mass Spectrometer Parameters (CI Analysis)                           | 10 |
| 8 | <b>D</b> ATA | Analysis   | 11 |
|   | 8.1          | Decision Criteria  | 11 |
|   | 8.1.1        | Chromatography   |    |
|   | 8.1.2        | , , ,  |    |
|   | 8.1.3        | Mass Spectrometry of BSTFA derivatives (EI data)                     | 11 |
|   | 8.1.4        | DART-TOF MS Data   | 12 |
|   |              |  |    |

Page 1 of 13

Issue Date: 02/11/2022

Archive Date: N/A

Issued By: Laboratory Director

TOX-313-06: Glycols Analysis in

Blood/Aqueous Samples

Status: Active

| 9  | REPORTING                   | 12 |
|----|-----------------------------|----|
| 10 | CORRECTIVE MEASURES         | 12 |
| 11 | Performance Characteristics | 12 |
| 1  | 1.1 LOD                     | 12 |
| 12 | LIMITATIONS                 | 12 |
| 13 | SAFETY                      | 12 |
| 14 | REVISION HISTORY            | 13 |

# Analysis of Poisonous Glycols from Blood and Aqueous Samples

#### 1 INTRODUCTION

Ethylene glycol (EG) and diethylene glycol (DEG) are two toxic glycols used in coolants and antifreezes. Triethylene glycol (TEG) is less toxic than EG and DEG, and can be used in plastics or air disinfectants. Propylene glycol (PG) or 1,2-propanediol is generally recognized as safe for use in foods, cosmetics and medicines. It can cause skin irritation and may be toxic in high doses in children.

#### 2 Scope

| Analyses  | ☑ Screening ☑ Confirmation ☐ Qua  | ntitation       |  |
|-----------|---|-----------------|--|
| Matrices  | Blood   | Aqueous Samples |  |
| Analytes  | EG  | EG              |  |
|           | DEG   |                 |  |
|           | TEG   |                 |  |
|           | PG  |                 |  |
| Personnel | This document applies to authorized personnel who perform the described |                 |  |
|           | tasks, singly or in combination.  |                 |  |

#### 3 PRINCIPLE

For screening or confirmation of EG in blood samples, specimens are crashed out with acetonitrile, taken to dryness, and derivatized with heptafluorobutyric anhydride (HFBA) before analysis by gas chromatography with mass spectrometry (electron ionization) [GC/MS(EI)]. For screening of multiple glycols in blood samples, or for a second test for confirming EG, samples are extracted in acetonitrile and converted to their trimethylsilyl derivatives for improved retention on a typical capillary column. Analysis of derivatized extracts is by GC/MS(EI) or GC/MS (chemical ionization) [GC/MS(CI)].

Aqueous samples are screened for EG via direct analysis in real time (DART) time of flight mass spectrometry (TOFMS). Positive findings will be confirmed via GC/MS.

#### 4 SPECIMEN CRITERIA

This procedure is validated for multiple glycols in blood. It is also validated for EG in aqueous samples. For blood, 0.5 ml of specimen is used for analysis of ethylene glycol and 0.25 ml for analysis of other glycols.

### 5 EQUIPMENT

### 5.1 Equipment

| Vortex mixer |  |  |  |
|--------------|--|--|--|
| Centrifuge   |  |  |  |

| TOX-313-06: Glycols Analysis in | Page 3 of 13 | Issue Date: 02/11/2022 |
|---------------------------------|--------------|------------------------|
| Blood/Aqueous Samples           | 0            | ,,,                    |

## Evaporator with nitrogen

Heating block

Adjustable volume pipettes with appropriate tips

Volumetric flasks (10 and 100 mL)

#### 5.2 Consumables

Test tubes (various)

Autosampler vials for Agilent GC/MS

Disposable glass pipettes

#### 5.3 Instruments

- A. Gas Chromatograph / Mass Spectrometer (GC/MS) capable of EI and CI ionization and equipped with a 30 m x 0.25 mm x 0.25  $\mu$ m film thickness DB-5 (or equivalent) column (dedicated to silyl derivatives)
- B. Gas Chromatograph / Mass Spectrometer (GC/MS) equipped with a 30 m x 0.25 mm x 0.25  $\mu$ m film thickness DB-5 (or equivalent) column
- C. Direct Analysis in Real Time Time-of-Flight Mass Spectrometer (DART TOFMS)

### 5.4 Software

| Component        | Software             | Version             |
|------------------|----------------------|---------------------|
| Operating System | Microsoft Windows    | XP Professional SP2 |
| GC/MS            | Xcalibur             | 2.0.7 SP1           |
|                  | Enhanced Chemstation | E.02.00.493         |

## 5.5 Chemicals/Reagents

### 5.5.1 Purchased

# Acetonitrile (HPLC grade)

Bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane (BSTFA/TMCS) (obtained from Sigma-Aldrich Chemical Company, or an equivalent supplier)

# Ethyl acetate (HPLC grade)

Heptafluorobutyric anhydride (HFBA), ≥99%, for GC derivatization

### Hexane (UV grade)

Sodium sulfate (Reagent grade)

| TOX-313-06: Glycols Analysis in<br>Blood/Agueous Samples | Page 4 of 13 | Issue Date: 02/11/2022 |
|--|--------------|------------------------|
|--|--------------|------------------------|

### 5.5.2 Prepared

### 5.6 Standards/Controls

Storage and stability are determined by supplier unless otherwise noted.

### 5.6.1 <u>Purchased/Stocks</u>

### Ethylene glycol (EG) Stock Standard (10 mg/mL)

Ethylene glycol traceable to United States Pharmacopoeia (USP) can be purchased from USP or another approved vendor.. Add 100 mg of EG to a 10-mL volumetric flask. Bring to the mark with acetonitrile and mix well to dissolve. Store refrigerated in glass; stable for at least 1 year.

## $d_4$ -Ethylene glycol ( $d_4$ -EG) Internal Standard Stock Standard (2.5 mg/mL)

 $d_4$ -Ethylene glycol can be purchased from Isotec or another approved vendor. Add 25 mg of  $d_4$ -EG to a 10-mL volumetric flask. Bring to the mark with acetonitrile and mix well to dissolve. Store refrigerated in glass; stable for at least 1 year.

# Diethylene glycol (DEG) Stock Standard (1 mg/mL)

Diethylene glycol can be purchased from Sigma-Aldrich or another approved vendor. Add 100 mg of DEG to a 100-mL volumetric flask. Bring to the mark with acetonitrile and mix well to dissolve. Store refrigerated in glass; stable for at least 1 year.

## Triethylene glycol (TEG) Stock Standard (1 mg/mL)

Triethylene glycol can be purchased from Sigma-Aldrich or another approved vendor. Add 100 mg of TEG to a 100-mL volumetric flask. Bring to the mark with acetonitrile and mix well to dissolve. Store refrigerated in glass; stable for at least 1 year.

### Propylene glycol (PG) or 1-2 Propanediol Stock Standard (1 mg/mL)

Propylene glycol can be purchased from Sigma-Aldrich or another approved vendor. Add 100 mg of PG to a 100-mL volumetric flask. Bring to the mark with acetonitrile and mix well to dissolve. Store refrigerated in glass; stable for at least 1 year.

### **Negative Control Blood**

Purchased from Cliniqa or another approved vendor. A Negative Control Blood sample is analyzed with every blood assay.

### **Negative Control Water**

Obtained from an appropriate commercial source or from the in-house tap. A Negative Control Water sample is analyzed with every water assay.

#### 5.6.2 Prepared

### EG Working Stock (500 μg/mL)

| TOX-313-06: Glycols Analysis in<br>Blood/Agueous Samples | Page 5 of 13 | Issue Date: 02/11/2022 |
|--|--------------|------------------------|
|--|--------------|------------------------|

Add 0.5 mL of the EG Stock Standard (10 mg/mL) to a 10-mL volumetric flask. Bring to the mark with acetonitrile and mix well to dissolve. Store refrigerated in glass; stable for at least 1 year.

## Positive Control Blood for BSTFA Derivatization (100 μg/mL)

Positive Controls will be prepared fresh. When 25  $\mu$ L of the appropriate 1 mg/mL stock solution, or 50  $\mu$ L of the EG Working Stock (500  $\mu$ g/mL) is added to 0.25 mL Negative Control Blood, the resulting control is 100  $\mu$ g/mL. A Positive Control will be prepared for each analyte of interest. TEG and DEG are routinely combined into one Positive Control, while EG and PG are typically analyzed individually.

# d4-Ethylene glycol (d4-EG) Internal Standard Solution (500 μg/mL)

Add 2.0 mL of d4-EG Internal Standard Stock Standard (2.5 mg/mL) to a 10-mL volumetric flask. Bring to the mark with deionized water and mix well to dissolve. Store refrigerated in glass; stable for at least 1 year.

# Positive Control Water (EG at 100 μg/mL)

Add 0.01 mL of the EG Control Stock Standard (10 mg/mL) to 0.99 mL of Negative Control Water. Prepare fresh. When sample size permits, an unknown sample can also be spiked with the EG Stock Standard as an additional Positive Control sample. A Positive Control Water sample is analyzed with every water assay.

## Positive Control Blood for HFBA Derivatization (EG at 72 μg/mL and 1200 μg/mL)

Positive Control Blood will be prepared on the day of analysis as described in Table 1.

Table 1: Blood Control Preparation (Prepared In Duplicate)

| Ctl Level | Blood Volume | μL EG<br>Working Stock (500 μg/mL) |  |  |
|-----------|--------------|------------------------------------|--|--|
| (μg/mL)   | (mL)         |                                    |  |  |
| 72        | 0.25         | 36                                 |  |  |
| 1200      | 0.25         | 600                                |  |  |

## 6 PROCEDURE

# 6.1 Screening for EG in Aqueous Matrices

Control and unknown samples are analyzed directly in duplicate on the DART-TOF MS using the instrumental parameters in Section 7 of this procedure. (No sample preparation is necessary.)

# 6.2 Screening or Confirmation of EG in Blood Specimens (HFBA Derivative)

| Step  |         | Note/Reference |
|---|---------|----------------|
| Label centrifuge tubes for each sample and control.   |         |                |
| Negative Control - Aliquot 0.25 mL of negative control blood.   | [iiiii] |                |
| Case Samples - Aliquot 0.25 mL in duplicate.  |         |                |
| Positive Controls - Aliquot 0.25 mL of negative control blood.  |         |                |
| Spike Controls according to Table 1 in 5.6.2 – EG Working Stock   |         |                |
| Add 50 $\mu$ L of the d4-EG Internal Standard Solution (500 $\mu$ g/mL) to one replicate of each sample and control. Note: The replicate without internal standard will be used for ion ratio comparison. | [iiiii] |                |
| Bring the total volume in the centrifuge tube to approximately 1.5 mL with acetonitrile.  | [!!!!]  |                |
| Vortex well.  |         |                |
| Centrifuge at approximately 10,000 rpm for 5 minutes.   |         |                |
| Remove the acetonitrile layer to a labeled 12 x 75 test tube.   |         |                |
| Evaporate to dryness under nitrogen at 50°C.  |         |                |
| Reconstitute extracts in 0.1 mL acetonitrile and vortex well.   |         |                |
| Add 50 μL HFBA.   |         |                |
| Cap with a snap cap and parafilm and vortex well.   |         |                |
| Heat at 60°C for 30 minutes.  |         |                |
| Cool to room temperature.   |         |                |
| Vortex with 0.5 mL hexane and 0.5 mL deionized water.   | [iiiii] |                |
| Centrifuge for 1 minute at approximately 3000 rpm.  |         |                |
| Remove hexane layer to a labeled 12 x 75 test tube.   |         |                |
| Add a small scoop of sodium sulfate (approximately 0.2 g) and vortex.   |         |                |
| Remove 0.05 mL of the hexane layer to a labeled autosampler vial.   |         |                |
| Add 0.1 mL hexane to each autosampler vial.   |         |                |

| TOX-313-06: Glycols Analysis in Blood/Aqueous Samples | Page 7 of 13 | Issue Date: 02/11/2022 |
|---|--------------|------------------------|
| blood/Aqueous sumples                                 |              | 1                      |

|     | Analyze 1 $\mu$ L by GC/MS(EI) using the parameters in Section 9.2 after ensuring that hexane is in the autosampler rinse vials.  |                |
|-----|---|----------------|
| 6.3 | Confirmation: EG, DEG, TEG, PG in Blood; EG in Aqueous Samples  |                |
|     | Step  | Note/Reference |
|     | Add 0.25 mL of specimen or control to an appropriately labeled $12 \times 75$ mm test tube.   |                |
|     | Spike positive controls, as appropriate.  |                |
|     | Add 0.5 mL acetonitrile to each sample.   |                |
|     | Cap and vortex for approximately 20 seconds.  |                |
|     | Centrifuge at approximately 2500 rpm for 2 minutes.   |                |
|     | Remove supernatant to a new 12 x 75 mm test tube.   |                |
|     | Evaporate the organic layer to dryness with nitrogen at approximately 40°C.   |                |
|     | Reconstitute the residue with 50 $\mu$ L BSTFA/TMCS.  |                |
|     | Cap tubes and incubate all samples at approximately 60°C in a heating block for at least 30 minutes.  |                |
|     | Allow extracts to cool down to room temperature. Transfer extracts to autosampler vials. Analyze 1 $\mu$ L by GC/MS(EI) or (CI) using the instrumental parameters in Section 7.3 of this procedure. It is important to analyze the extracts on a GC column that is dedicated to silyl derivatives. To compensate for known carryover within this procedure, ethyl acetate blanks and BSTFA/TMCS blanks should precede every unknown sample. |                |

# 7 ANALYTICAL PARAMETERS

# 7.1 DART-TOF MS Analysis

# 7.1.1 <u>DART Ionization Source Parameters:</u>

| Anode Polarity:       | Positive (+)               |
|-----------------------|----------------------------|
| Needle Voltage:       | 3999 V                     |
| Electrode #1 Voltage: | 75 V                       |
| Electrode #2 Voltage: | 150 V                      |
| Gas Control:          | ~ 2.4 LPM                  |
| Temperature Control:  | set 410°C (actual ~ 400°C) |

# 7.1.2 <u>TOF-MS Parameters:</u>

| Tune File: DART_+  |            |  |
|--------------------|------------|--|
| Needle Voltage:    | 0 V        |  |
| Ring Lens Voltage: | 5 V        |  |
| Orifice 1 Voltage: | 30 V       |  |
| Orifice 2 Voltage: | 5 V        |  |
| Peaks Voltage:     | 300 V      |  |
| Mass Range:        | 43-500 m/z |  |

# 7.2 GC/MS Parameters for HFBA Derivative

# 7.2.1 GC Parameters

| Oven Parameters |          | Inlet and Carrier Parameters |            | Column Parameters |         |
|-----------------|----------|------------------------------|------------|-------------------|---------|
| temperature 1   | 40°C     | inlet                        | 300ºC      | type              | DB-5    |
|                 |          | temperature                  |            |                   |         |
| hold 1          | 1 min    | injection mode               | split      | length            | 30 m    |
| ramp 1          | 10ºC/min | split                        | 10:1       | internal          | 0.25 mm |
|                 |          |                              |            | diameter          |         |
| temperature 2   | 130ºC    | carrier gas                  | ultrapure  | film thickness    | 0.25 μm |
|                 |          |                              | helium     |                   |         |
| ramp 2          | 30ºC/min | carrier mode                 | constant   |                   |         |
|                 |          |                              | flow       |                   |         |
| temperature 3   | 325ºC    | flow                         | 1.2 mL/min |                   |         |

# hold 2 1.5 min

# 7.2.2 <u>Mass Spectrometer Parameters</u>

| ionization mode | electron ionization<br>(+) | source temperature           | 230ºC |
|-----------------|----------------------------|------------------------------|-------|
| scan mode       | full scan                  | transfer line<br>temperature | 280º℃ |

| TOX-313-06: Glycols Analysis in | Page 9 of 13 | Issue Date: 02/11/2022 |
|---------------------------------|--------------|------------------------|
| Blood/Aqueous Samples           |              | ,,,,                   |

| scan range | 35 - 500 m/z | quad temperature | 150°C   |
|------------|--------------|------------------|---------|
|            |              | solvent delay    | 5.0 min |

# 7.3 GC/MS Parameters for BSTFA Derivatives

# 7.3.1 GC Parameters

| Oven Parameter | rs       | Inlet and Carrier Parameters |            | Column Parameters |         |
|----------------|----------|------------------------------|------------|-------------------|---------|
| temperature 1  | 60°C     | inlet                        | 250ºC      | type              | DB-5    |
|                |          | temperature                  |            |                   |         |
| hold 1         | 2 min    | injection mode               | splitless  | length            | 30 m    |
| ramp 1         | 10ºC/min | carrier gas                  | ultrapure  | internal          | 0.25 mm |
|                |          |                              | helium     | diameter          |         |
| temperature 2  | 180ºC    | carrier mode                 | constant   | film thickness    | 0.25 μm |
|                |          |                              | flow       |                   |         |
| ramp 2         | 35ºC/min | Flow rate                    | 1.2 mL/min |                   |         |
| temperature 3  | 250ºC    |                              |            |                   |         |
| hold 2         | 10 min   |                              |            |                   |         |

# 7.3.2 Mass Spectrometer Parameters (El Analysis)

| ionization mode | electron ionization (+) | source temperature           | 230ºC   |
|-----------------|-------------------------|------------------------------|---------|
| scan mode       | full scan               | transfer line<br>temperature | 270ºC   |
| scan range      | 70 - 500 m/z            | solvent delay                | 5.0 min |
|                 |                         | quad temperature             | 150ºC   |

# 7.3.3 <u>Mass Spectrometer Parameters (CI Analysis)</u>

| ionization mode | methane chemical ionization (+) | source temperature           | 230º℃   |
|-----------------|---------------------------------|------------------------------|---------|
| scan mode       | full scan                       | transfer line<br>temperature | 270ºC   |
| scan range      | 70 - 500 m/z                    | solvent delay                | 5.2 min |
|                 |                                 | quad temperature             | 150ºC   |

Issue Date: 02/11/2022

#### 8 DATA ANALYSIS

#### 8.1 Decision Criteria

The following criteria are used as guidelines in determining the acceptability of the data produced in this procedure. In general, compound identification will be based on comparison of the chromatography and mass spectrometry for the analyte peak of interest with data from a contemporaneously analyzed reference standard or Positive Control. In most cases, all of the below should be met in order to identify one of the target analytes within a biological specimen.

## 8.1.1 <u>Chromatography</u>

The peak of interest should show good chromatographic fidelity, with reasonable peak shape, width, and resolution. It is noted, however, that derivatized glycols often produce wide chromatographic peaks on the analytical column used in this procedure. In order to be determined acceptable, a chromatographic peak in an unknown sample should compare favorably to a chromatographic peak of the same analyte in a known sample analyzed on the same system in the same or subsequent analytical runs. Additionally, the following two criteria should be met.

#### 8.1.1.1 Retention Time

The retention time of the peak should be within ±2% of the retention time (relative or absolute) obtained from injection of an extracted Positive Control.

## 8.1.1.2 Signal-to-Noise

To justify the existence of a peak, its signal-to-noise ratio should exceed 3. Further, the baseline signal for the peak from the sample of interest should be at least 10-fold greater than that for any observed peak at a similar retention time in a Negative Control or solvent blank injected just prior to that sample.

### 8.1.2 Mass Spectrometry of HFBA derivative of EG

The following ions may be traced for ion ratio comparison of an unknown to a positive control: 169, 197, 213, 241. Only the 241 and 213 ions are from the EG; the other ions are from the HFBA. Therefore, the 169 and 197 will be present in the EI spectrum of the d4-EG-HFBA derivative as well. For this reason, it is best to use samples with no internal standard added for ion ratio comparisons.

Detectable 255 ion in a peak eluting near the internal standard may indicate the presence of PG. If the 255 ion is detected in an unknown near the retention time of the internal standard (within a few scans), this sample should be analyzed by a different method to verify that PG is not present, as it may interfere with the identification of EG.

# 8.1.3 <u>Mass Spectrometry of BSTFA</u> derivatives (EI data)

The following ions may be traced for each analyte:

| TOX-313-06: Glycols Analysis in | Page 11 of 13 | Issue Date: 02/11/2022 |
|---------------------------------|---------------|------------------------|
| Blood/Aqueous Samples           | Page 11 01 13 | 155ue Date. 02/11/2022 |

• EG: 191, 133, 103, 147

• PG: 133, 147, 117

• DEG: 103, 147, 117

• TEG: 103, 147, 161

The mass spectrum of the analyte of interest should match that of a reference standard, extracted calibrator, or an extracted Positive Control. See TOX-104 for further guidance.

### 8.1.4 DART-TOF MS Data

The following two ions are used to screen for EG in aqueous samples: 63.0446 and 45.0340 (EG – water). Unknown samples should be spiked with EG at a concentration of  $100 \,\mu\text{g/mL}$  to rule out the possibility of false negative results if the sample may not be pure water and if sample size permits.

### 9 REPORTING

Reference TOX-100 and TOX-101 for guidance.

#### **10** CORRECTIVE MEASURES

Reference TOX-100 and TOX-101 for guidance.

#### 11 Performance Characteristics

#### 11.1 LOD

The limit of detection has been administratively set to 100  $\mu g/mL$  for DEG, TEG and PG in blood samples.

The limit of detection has been administratively set to 25 μg/mL for EG in blood samples.

The limit of detection for EG in aqueous samples is 100 µg/mL

#### 12 LIMITATIONS

There are only two ions in the HFBA derivative of EG that are unique to EG. The other ions that are found in the MS of the EG-HFBA derivative are HFBA ions.

Interferences: EG cannot be accurately identified using the HFBA derivative method in the presence of PG. Grossly decomposed or putrefied samples may affect detection limits.

#### 13 SAFETY

The derivatizing reagents used in this procedure have noxious odors. They should be used in the fume hood to prevent excess exposure to their odor.

Take standard precautions for the handling of chemicals and biological materials. Refer to the FBI Laboratory Safety Manual for guidance.

# 14 REVISION HISTORY

| Revision      | Issued             | Changes                        |
|---------------|--------------------|--------------------------------|
| 06 02/11/2022 | Document reformat. |                                |
| 00            | 02/11/2022         | Minor text updates throughout. |